CSL reports a US$2.6 billion loss as markets assess CSL stock

Published on 10/27/2026 at 09:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2027 guidance targets 5 percent underlying NPAT growth. CSL stock costs EUR 123.33 on October 27, 2026 in trading.

Fiscal reset and near-term milestones

CSL reported a US$2.6 billion statutory loss for fiscal 2026 on October 27, 2026.
Fiscal 2027 guidance targets 5 percent growth in underlying net profit after tax.
CSL stock traded at EUR 123.33 at 9:31 a.m. CET at Lang & Schwarz on October 27, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited (AU000000CSL8) traded at EUR 123.33 at Lang & Schwarz on October 27, 2026, at 9:31 a.m. CET, as the biotechnology group reported a US$2.6 billion statutory loss for fiscal 2026. According to TradingView on October 27, 2026, revenue fell 1 percent to US$15.8 billion and underlying net profit after tax declined 3 percent to US$2.8 billion.

Fiscal results expose the reset

The headline loss was far weaker than the underlying result. CSL reported underlying net profit after tax before amortization of US$3.1 billion in fiscal 2026, down 2 percent from the prior year, while impairment and restructuring charges pushed the reported result into negative territory.

The outlook offers a measurable recovery test. Management expects fiscal 2027 revenue to remain broadly in line with fiscal 2026, while underlying net profit after tax is forecast to grow 5 percent on a constant-currency basis. That combination places the burden on cost savings, product mix and operating efficiency rather than broad sales expansion.

What milestones answer the growth question?

The company has a clear three-step chronology. On October 5, 2026, CSL and Alentis Therapeutics agreed a rare-disease development deal worth up to US$1.6 billion, according to FinanzNachrichten. On October 21, 2026, CSL named Deborah Waterhouse as its next chief executive officer, effective February 1, 2027, as reported by Business News Today. The October 27 results then quantified the financial reset with the US$2.6 billion statutory loss.

The next dates are also defined. CSL's annual general meeting is scheduled for October 27, 2026, according to the CSL investor page. Fiscal 2027 half-year results are scheduled for February 10, 2027, according to Business News Today.

Valuation now depends on execution

CSL's recovery case rests on a profitable core, but the revenue profile remains uneven. Behring and Seqirus are expected to support growth, while Vifor remains a drag on group sales. The 5 percent underlying profit target can therefore be achieved through savings and mix even before consolidated revenue accelerates.

For investors, the next evidence will come from operating cash generation, division-level sales and the delivery of the new leadership plan. The statutory loss highlights the cost of the reset, while the underlying result shows why management can still fund investment and restructuring.

CSL stock was trading at EUR 123.33 at Lang & Schwarz on October 27, 2026, at 9:31 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of CSL stock.